Remove 2029 Remove Patients Remove Side effects
article thumbnail

NICE recommends AbbVie’s/J&J’s Imbruvica for combo use in untreated CLL

Pharmaceutical Technology

The British institute that oversees a therapy’s cost-effectiveness opted for the recommendation based on clinical data from the Phase II CAPTIVATE and the Phase III GLOW studies. The combination therapy also caused fewer side effects, with heart problems and hypertension as the most common ones, based on the final draft guidance.

article thumbnail

Digitalisation of the clinical trial landscape

European Pharmaceutical Review

According to Maximize Market Research , new technologies are expected to boost the clinical trials market between 2022 to 2029, especially as the industry and patients are shifting towards digitalisation approaches and personalised medicines.

Safety 111
article thumbnail

Managing the next pandemic: the role of nasal vaccine administration

European Pharmaceutical Review

It was about solving cold-chain logistical challenges and ensuring the vaccine doses themselves could be administered easily and efficiently with minimal discomfort for patients. million by 2029, up from $122.287 million in 2021. We have been given a crash course in how to deliver vaccine doses successfully to billions of people.